Aptose Biosciences Inc. (T:APS*CA)

Business Focus: Biotechnology & Medical Research (NEC)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
Company Contact
Address: 251 Consumers Rd Suite 1105
NORTH YORK ON M2J 4R3
Tel: N/A
Website: https://aptose.com
IR: See website
<
Key People
William Glenn Rice
Chairman of the Board, President, Chief Executive Officer
Fletcher Payne
Chief Financial Officer, Senior Vice President, Chief Business Officer
Rafael Bejar
Senior Vice President, Chief Medical Officer
Philippe Ledru
Senior Vice President, Chief Commercial Officer
   
Business Overview
Aptose Biosciences Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of precision medicines addressing unmet clinical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (HM43239), an oral, myeloid kinase inhibitor being studied as monotherapy and in combination therapy in the APTIVATE international Phase I/II expansion trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib (CG-806), an oral, dual lymphoid and myeloid kinase inhibitor in Phase I a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies.
Financial Overview
For the fiscal year ended 31 December 2023, Aptose Biosciences Inc revenues was not reported. Net loss increased 22% to $51.2M. Higher net loss reflects General and administrative excluding sal increase of 16% to $13.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$6.80 to -$7.58.
Employees: 35 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $22.61M as of Dec 31, 2023
Annual revenue (TTM): $0.00M as of Dec 31, 2023
EBITDA (TTM): -$70.76M as of Dec 31, 2023
Net annual income (TTM): -$69.32M as of Dec 31, 2023
Free cash flow (TTM): -$60.37M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 15,717,701 as of Mar 26, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.